In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 143-148

  King, Paula ^a   Lomovskaya, Olga ^a   Griffith, David C ^a   Burns, Jane L ^b   Dudley, Michael N ^a  

^a Mpex Pharmaceuticals Inc   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AZTREONAM; CIPROFLOXACIN; LEVOFLOXACIN; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ARTICLE; BACTERIUM ISOLATE; BIOFILM; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; LUNG FIBROSIS; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

AEROSOLS; ANTI-BACTERIAL AGENTS; BACTERIA; BIOFILMS; CHRONIC DISEASE; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; SPUTUM;

EID: 73849128431     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00248-09     Document Type: Article

References (41)

1. Beringer, P. M., A. A. Vinks, R. W. Jelliffe, and B. J. Shapiro. 2000. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob. Agents Chemother. 44:809-813.
2. Burns, J. L. 2002. Emergence of new pathogens in CF: the devil we know or the devil we don't know? J. Pediatr. 140:283-284.
3. Burns, J. L., J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. 1999. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179:1190-1196.
4. Canton, R., S. Valdezate, A. Vindel, B. Sanchez Del Saz, L. Maiz, and F. Baquero. 2003. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates. Pediatr. Pulmonol. 35:99-107.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Dalhoff, A., and F. J. Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22: 203-221.
7. Dasenbrook, E. C., C. A. Merlo, M. Diener-West, N. Lechtzin, and M. P. Boyle. 2008. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:814-821.
8. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
9. Dudley, M. N., J. Loutit, and D. C. Griffith. 2008. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr. Opin. Biotechnol. 19:637-643.
10. FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9.
11. Gales, A. C., R. N. Jones, S. S. Andrade, and H. S. Sader. 2005. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). Mem. Inst. Oswaldo Cruz 100:571-577.
12. Geller, D. E., P. Flume, R. Schwab, P. Fomos, D. Conrad, E. Morgan, D. Griffith, O. Lomovskaya, J. Loutit, and M. N. Dudley. 2008. A phase I safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients. Pediatr. Pulmonol. 43(Suppl.):S31.
13. Geller, D. E., W. H. Pitlick, P. A. Nardella, W. G. Tracewell, and B. W. Ramsey. 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122:219-226.
14. Gibson, R. L., G. Z. Retsch-Bogart, C. Oermann, C. Milla, J. Pilewski, C. Daines, R. Ahrens, K. Leon, M. Cohen, S. McNamara, T. L. Callahan, R. Markus, and J. L. Burns. 2006. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41:656-665.
15. Gillespie, T., and R. G. Masterton. 2002. Investigation into the selection frequency of resistant mutants and the bacterial kill rate by levofloxacin and ciprofloxacin in non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Int. J. Antimicrob. Agents 19:377-382.
16. Golini, G., F. Favari, F. Marchetti, and R. Fontana. 2004. Bacteriostatic and bactericidal activity of levofloxacin against clinical isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 23:798-800.
17. Griffith, D. C., C. Hansen, T. Pressler, T. Balchen, T. Jon Jensen, D. E. Geller, K. Kesser, J. Rock, M. Surber, K. Bostian, and M. N. Dudley. 2008. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications. J. Cyst. Fibros. 7(Suppl.):S2.
18. Hoban, D. J., S. K. Bouchillon, J. L. Johnson, G. G. Zhanel, D. L. Butler, L. A. Miller, and J. A. Poupard. 2001. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Eur. J. Clin. Microbiol. Infect. Dis. 20:814-819.
19. Hoffman, L. R., D. A. D'Argenio, M. J. MacCoss, Z. Zhang, R. A. Jones, and S. I. Miller. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171-1175.
20. Hunt, B. E., A. Weber, A. Berger, B. Ramsey, and A. L. Smith. 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39:34-39.
21. Isenberg, H. D., P. Alperstein, and K. France. 1999. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn. Microbiol. Infect. Dis. 33:81-86.
22. Ishida, H., Y. Ishida, Y. Kurosaka, T. Otani, K. Sato, and H. Kobayashi. 1998. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 42:1641-1645.
23. King, P., K. Senekeo-Effenberger, T. Nolan, O. Lomovskaya, M. N. Dudley, and D. C. Griffith. 2008. In vitro PK-PD of levofloxacin (LVX): a new dosing paradigm for aerosolized antibiotics, abstr. A-042. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Lechtzin, N., M. John, R. Irizarry, C. Merlo, G. B. Diette, and M. P. Boyle. 2006. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73:27-33.
25. Lomovskaya, O., A. Lee, K. Hoshino, H. Ishida, A. Mistry, M. S. Warren, E. Boyer, S. Chamberland, and V. J. Lee. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1340-1346.
26. Mah, T. F., B. Pitts, B. Pellock, G. C. Walker, P. S. Stewart, and G. A. O'Toole. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310.
27. McKnight, A. J., A. Shaw, C. E. Goldsmith, L. Clarke, B. C. Millar, J. McCaughan, J. S. Elborn, A. Reid, and J. E. Moore. 2005. Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland. Br. J. Biomed Sci. 62:30-32.
28. Mendelman, P. M., A. L. Smith, J. Levy, A. Weber, B. Ramsey, and R. L. Davis. 1985. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132:761-765.
29. Merlo, C. A., M. P. Boyle, M. Diener-West, B. C. Marshall, C. H. Goss, and N. Lechtzin. 2007. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132:562-568.
30. Miller, M. B., and P. H. Gilligan. 2003. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J. Clin. Microbiol. 41:4009-4015.
31. Moskowitz, S. M., J. M. Foster, J. Emerson, and J. L. Burns. 2004. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42:1915-1922.
32. Noviello, S., F. Ianniello, S. Leone, and S. Esposito. 2003. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J. Antimicrob. Chemother. 52:869-872.
33. Oliver, A., R. Canton, P. Campo, F. Baquero, and J. Blazquez. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1254.
34. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
35. Prunier, A. L., B. Malbruny, M. Laurans, J. Brouard, J. F. Duhamel, and R. Leclercq. 2003. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J. Infect. Dis. 187:1709-1716.
36. Ramsey, B. W., M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall, S. Marshall, and A. L. Smith. 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340:23-30.
37. Sagel, S. D., R. L. Gibson, J. Emerson, S. McNamara, J. L. Burns, J. S. Wagener, and B. W. Ramsey. 2009. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Pediatr. 154:183-188.
38. Traczewski, M. M., and S. D. Brown. 2006. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother. 50:819-821.
39. Van Bambeke, F., J. M. Michot, J. Van Eldere, and P. M. Tulkens. 2005. Quinolones in 2005: an update. Clin. Microbiol. Infect. 11:256-280.
40. Visalli, M. A., S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.
41. Weiss, K., C. Restieri, E. De Carolis, M. Laverdiere, and H. Guay. 2000. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 45:363-365.